Basanth B. Eedara

18 Frederick St
Dunedin, OTA 9054, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.

Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.

Journal: Pharmaceutics

Published: June 15, 2025

Organic solution advanced spray-dried microparticulate dry powder of doxycycline hyclate for lung delivery.

Organic solution advanced spray-dried microparticulate dry powder of doxycycline hyclate for lung delivery.

Journal: Scientific reports

Published: February 24, 2025

Innovative Dual Combination Cospray-Dried Rock Inhibitor/l-Carnitine Inhalable Dry Powder Aerosols.

Innovative Dual Combination Cospray-Dried Rock Inhibitor/l-Carnitine Inhalable Dry Powder Aerosols.

Journal: ACS bio & med chem Au

Published: July 20, 2024

Inhalable Advanced Co-Spray Dried Microparticles/Nanoparticles of a Novel RhoA/Rho Kinase Inhibitor with Lung Surfactant Biomimetic Phospholipids for Targeted Lung Delivery.

Inhalable Advanced Co-Spray Dried Microparticles/Nanoparticles of a Novel RhoA/Rho Kinase Inhibitor with Lung Surfactant Biomimetic Phospholipids for Targeted Lung Delivery.

Journal: ACS pharmacology & translational science

Published: July 19, 2024

Design and comprehensive characterization of dry powder inhalation aerosols of simvastatin DPPC/DPPG lung surfactant-mimic nanoparticles/microparticles for pulmonary nanomedicine.

Design and comprehensive characterization of dry powder inhalation aerosols of simvastatin DPPC/DPPG lung surfactant-mimic nanoparticles/microparticles for pulmonary nanomedicine.

Journal: RSC advances

Published: July 09, 2024

Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.

Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.

Journal: International journal of pharmaceutics

Published: December 13, 2023

Comprehensive Physicochemical Characterization, In Vitro Membrane Permeation, and In Vitro Human Skin Cell Culture of a Novel TOPK Inhibitor, HI-TOPK-032.

Comprehensive Physicochemical Characterization, In Vitro Membrane Permeation, and In Vitro Human Skin Cell Culture of a Novel TOPK Inhibitor, HI-TOPK-032.

Journal: International journal of molecular sciences

Published: September 13, 2023

Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization.

Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization.

Journal: Pharmaceutics

Published: July 17, 2023

Editorial: Strategies to overcome the barriers to effective inhaled treatments.

Editorial: Strategies to overcome the barriers to effective inhaled treatments.

Journal: Frontiers in drug delivery

Published: July 06, 2023

Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation.

Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation.

Journal: International journal of molecular sciences

Published: March 05, 2023

Dissolution and Absorption of Inhaled Drug Particles in the Lungs.

Dissolution and Absorption of Inhaled Drug Particles in the Lungs.

Journal: Pharmaceutics

Published: September 30, 2022

Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols.

Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols.

Journal: Pharmaceutics

Published: July 27, 2022

Showing 1-12 of 29

Last Updated: 09/26/2026